152 related articles for article (PubMed ID: 35861435)
21. Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC).
Sherwood JL; Corcoran C; Brown H; Sharpe AD; Musilova M; Kohlmann A
PLoS One; 2016; 11(2):e0150197. PubMed ID: 26918901
[TBL] [Abstract][Full Text] [Related]
22. Sensitive Quantification of Cell-Free Tumor DNA for Early Detection of Recurrence in Colorectal Cancer.
Stasik S; Mende M; Schuster C; Mahler S; Aust D; Tannapfel A; Reinacher-Schick A; Baretton G; Krippendorf C; Bornhäuser M; Ehninger G; Folprecht G; Thiede C
Front Genet; 2021; 12():811291. PubMed ID: 35069704
[TBL] [Abstract][Full Text] [Related]
23. Circulating Cell-Free DNA Yield and Circulating-Tumor DNA Quantity from Liquid Biopsies of 12 139 Cancer Patients.
Huang RSP; Xiao J; Pavlick DC; Guo C; Yang L; Jin DX; Fendler B; Severson E; Killian JK; Hiemenz M; Duncan D; Lin DI; Dennis L; Aiyer A; Gjoerup O; Oxnard G; Venstrom J; Elvin J; Ramkissoon SH; Ross JS
Clin Chem; 2021 Nov; 67(11):1554-1566. PubMed ID: 34626187
[TBL] [Abstract][Full Text] [Related]
24. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
[TBL] [Abstract][Full Text] [Related]
25. Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation.
Dao J; Conway PJ; Subramani B; Meyyappan D; Russell S; Mahadevan D
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686024
[TBL] [Abstract][Full Text] [Related]
26. Structural variation and fusion detection using targeted sequencing data from circulating cell free DNA.
Gawroński AR; Lin YY; McConeghy B; LeBihan S; Asghari H; Koçkan C; Orabi B; Adra N; Pili R; Collins CC; Sahinalp SC; Hach F
Nucleic Acids Res; 2019 Apr; 47(7):e38. PubMed ID: 30759232
[TBL] [Abstract][Full Text] [Related]
27. High-throughput and affordable genome-wide methylation profiling of circulating cell-free DNA by methylated DNA sequencing (MeD-seq) of LpnPI digested fragments.
Deger T; Boers RG; de Weerd V; Angus L; van der Put MMJ; Boers JB; Azmani Z; van IJcken WFJ; Grünhagen DJ; van Dessel LF; Lolkema MPJK; Verhoef C; Sleijfer S; Martens JWM; Gribnau J; Wilting SM
Clin Epigenetics; 2021 Oct; 13(1):196. PubMed ID: 34670587
[TBL] [Abstract][Full Text] [Related]
28. Optimizing blood collection, transport and storage conditions for cell free DNA increases access to prenatal testing.
Wong D; Moturi S; Angkachatchai V; Mueller R; DeSantis G; van den Boom D; Ehrich M
Clin Biochem; 2013 Aug; 46(12):1099-1104. PubMed ID: 23643886
[TBL] [Abstract][Full Text] [Related]
29. A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR.
Norton SE; Lechner JM; Williams T; Fernando MR
Clin Biochem; 2013 Oct; 46(15):1561-5. PubMed ID: 23769817
[TBL] [Abstract][Full Text] [Related]
30. Preanalytical blood sample workup for cell-free DNA analysis using Droplet Digital PCR for future molecular cancer diagnostics.
van Ginkel JH; van den Broek DA; van Kuik J; Linders D; de Weger R; Willems SM; Huibers MMH
Cancer Med; 2017 Oct; 6(10):2297-2307. PubMed ID: 28940814
[TBL] [Abstract][Full Text] [Related]
31. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients.
Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W
Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850
[TBL] [Abstract][Full Text] [Related]
32. IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing.
Deans ZC; Butler R; Cheetham M; Dequeker EMC; Fairley JA; Fenizia F; Hall JA; Keppens C; Normanno N; Schuuring E; Patton SJ
Virchows Arch; 2019 Jun; 474(6):681-689. PubMed ID: 31028539
[TBL] [Abstract][Full Text] [Related]
33. Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours.
Stankunaite R; George SL; Gallagher L; Jamal S; Shaikh R; Yuan L; Hughes D; Proszek PZ; Carter P; Pietka G; Heide T; James C; Tari H; Lynn C; Jain N; Portela LR; Rogers T; Vaidya SJ; Chisholm JC; Carceller F; Szychot E; Mandeville H; Angelini P; Jesudason AB; Jackson M; Marshall LV; Gatz SA; Anderson J; Sottoriva A; Chesler L; Hubank M
Eur J Cancer; 2022 Feb; 162():209-220. PubMed ID: 34933802
[TBL] [Abstract][Full Text] [Related]
34. Genotyping of circulating cell-free DNA enables noninvasive tumor detection in myxoid liposarcomas.
Braig D; Becherer C; Bickert C; Braig M; Claus R; Eisenhardt AE; Heinz J; Scholber J; Herget GW; Bronsert P; Fricke A; Follo M; Stark GB; Bannasch H; Eisenhardt SU
Int J Cancer; 2019 Aug; 145(4):1148-1161. PubMed ID: 30779112
[TBL] [Abstract][Full Text] [Related]
35. Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid.
Mehrotra M; Singh RR; Chen W; Huang RSP; Almohammedsalim AA; Barkoh BA; Simien CM; Hernandez M; Behrens C; Patel KP; Routbort MJ; Broaddus RR; Medeiros LJ; Wistuba II; Kopetz S; Luthra R
J Mol Diagn; 2017 Jul; 19(4):514-524. PubMed ID: 28506684
[TBL] [Abstract][Full Text] [Related]
36. Detection of tumor-derived extracellular vesicles in plasma from patients with solid cancer.
Vitale SR; Helmijr JA; Gerritsen M; Coban H; van Dessel LF; Beije N; van der Vlugt-Daane M; Vigneri P; Sieuwerts AM; Dits N; van Royen ME; Jenster G; Sleijfer S; Lolkema M; Martens JWM; Jansen MPHM
BMC Cancer; 2021 Mar; 21(1):315. PubMed ID: 33761899
[TBL] [Abstract][Full Text] [Related]
37. The effect of surgical trauma on circulating free DNA levels in cancer patients-implications for studies of circulating tumor DNA.
Henriksen TV; Reinert T; Christensen E; Sethi H; Birkenkamp-Demtröder K; Gögenur M; Gögenur I; Zimmermann BG; ; Dyrskjøt L; Andersen CL
Mol Oncol; 2020 Aug; 14(8):1670-1679. PubMed ID: 32471011
[TBL] [Abstract][Full Text] [Related]
38. Specialized Blood Collection Tubes for Liquid Biopsy: Improving the Pre-analytical Conditions.
Sorber L; Zwaenepoel K; Jacobs J; De Winne K; Van Casteren K; Augustus E; Lardon F; Prenen H; Peeters M; Van Meerbeeck J; Roeyen G; Rolfo C; Pauwels P
Mol Diagn Ther; 2020 Feb; 24(1):113-124. PubMed ID: 31838654
[TBL] [Abstract][Full Text] [Related]
39. Investigation of Preanalytical Variables Impacting Pathogen Cell-Free DNA in Blood and Urine.
Murugesan K; Hogan CA; Palmer Z; Reeve B; Theron G; Andama A; Somoskovi A; Steadman A; Madan D; Andrews J; Croda J; Sahoo MK; Cattamanchi A; Pinsky BA; Banaei N
J Clin Microbiol; 2019 Nov; 57(11):. PubMed ID: 31511335
[TBL] [Abstract][Full Text] [Related]
40. Statistical analysis of mutant allele frequency level of circulating cell-free DNA and blood cells in healthy individuals.
Xia L; Li Z; Zhou B; Tian G; Zeng L; Dai H; Li X; Liu C; Lu S; Xu F; Tu X; Deng F; Xie Y; Huang W; He J
Sci Rep; 2017 Aug; 7(1):7526. PubMed ID: 28790338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
